Compare Stocks: ABUS, VKTX, TLX, and IOVA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$5.12 -1.1%	$4.78	$3.50 ▼ $5.45	$1.02B	0.62	2.36 million shs	341,658 shs
IOVA Iovance Biotherapeutics	$8.25 -2.2%	$6.17	$1.76 ▼ $9.36	$3.75B	0.83	15.40 million shs	2.00 million shs
TLX Telix Pharmaceuticals	$12.09 -2.0%	$11.24	$6.28 ▼ $12.48	$4.11B	-0.17	196,913 shs	130,271 shs
VKTX Viking Therapeutics	$32.32 -1.2%	$35.12	$22.96 ▼ $43.15	$3.77B	0.69	2.48 million shs	675,834 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	-0.19%	+1.37%	+12.64%	+20.51%	+19.40%
IOVA Iovance Biotherapeutics	-3.10%	-2.20%	+31.72%	+112.61%	+255.70%
TLX Telix Pharmaceuticals	+3.01%	+7.77%	+4.66%	+30.58%	+32.83%
VKTX Viking Therapeutics	-2.91%	-2.39%	-5.05%	+14.30%	+29.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$5.12 -1.1%	$4.78	$3.50 ▼ $5.45	$1.02B	0.62	2.36 million shs	341,658 shs
IOVA Iovance Biotherapeutics	$8.25 -2.2%	$6.17	$1.76 ▼ $9.36	$3.75B	0.83	15.40 million shs	2.00 million shs
TLX Telix Pharmaceuticals	$12.09 -2.0%	$11.24	$6.28 ▼ $12.48	$4.11B	-0.17	196,913 shs	130,271 shs
VKTX Viking Therapeutics	$32.32 -1.2%	$35.12	$22.96 ▼ $43.15	$3.77B	0.69	2.48 million shs	675,834 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	-0.19%	+1.37%	+12.64%	+20.51%	+19.40%
IOVA Iovance Biotherapeutics	-3.10%	-2.20%	+31.72%	+112.61%	+255.70%
TLX Telix Pharmaceuticals	+3.01%	+7.77%	+4.66%	+30.58%	+32.83%
VKTX Viking Therapeutics	-2.91%	-2.39%	-5.05%	+14.30%	+29.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	2.50	Moderate Buy	$5.00	-2.25% Downside
IOVA Iovance Biotherapeutics	2.45	Hold	$8.89	7.81% Upside
TLX Telix Pharmaceuticals	2.86	Moderate Buy	$20.40	68.73% Upside
VKTX Viking Therapeutics	2.75	Moderate Buy	$96.63	199.01% Upside

Current Analyst Ratings Breakdown

Latest ABUS, VKTX, TLX, and IOVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/26/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/24/2026	IOVA Iovance Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$7.00 ➝ $10.00
8/21/2026	TLX Telix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Hold (C-)
8/20/2026	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$4.00 ➝ $7.00
8/20/2026	TLX Telix Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
8/18/2026	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$10.00 ➝ $11.00
8/18/2026	VKTX Viking Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/11/2026	VKTX Viking Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$75.00 ➝ $65.00

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$14.08M	71.97	N/A	N/A	$0.40 per share	12.79
IOVA Iovance Biotherapeutics	$263.50M	14.17	N/A	N/A	$1.76 per share	4.68
TLX Telix Pharmaceuticals	$803.79M	5.11	$0.04 per share	284.13	$1.23 per share	9.83
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$5.65 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$33.50M	$0.79	6.49	N/A	N/A	84.22%	90.98%	82.34%	11/16/2026 (Estimated)
IOVA Iovance Biotherapeutics	-$390.98M	-$0.73	N/A	N/A	N/A	-89.11%	-40.51%	-31.65%	11/5/2026 (Estimated)
TLX Telix Pharmaceuticals	-$7.12M	N/A	N/A	201.50	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	-$359.64M	-$4.66	N/A	N/A	N/A	N/A	-94.56%	-82.75%	10/28/2026 (Estimated)

Latest ABUS, VKTX, TLX, and IOVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ABUS Arbutus Biopharma	-$0.02	-$0.03	-$0.01	-$0.03	$0.70 million	$1.01 million
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	-$0.11	+$0.0235	-$0.11	$87.83 million	$198.63 million
7/29/2026	Q2 2026	VKTX Viking Therapeutics	-$1.21	-$1.10	+$0.11	-$1.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	81.42	81.42
IOVA Iovance Biotherapeutics	N/A	4.34	3.82
TLX Telix Pharmaceuticals	1.16	2.01	1.85
VKTX Viking Therapeutics	N/A	4.72	4.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
IOVA Iovance Biotherapeutics	77.03%
TLX Telix Pharmaceuticals	N/A
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	19.90%
IOVA Iovance Biotherapeutics	7.80%
TLX Telix Pharmaceuticals	N/A
VKTX Viking Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	198.11 million	158.68 million	Optionable
IOVA Iovance Biotherapeutics	500	452.97 million	417.64 million	Optionable
TLX Telix Pharmaceuticals	1,184	339.78 million	N/A	N/A
VKTX Viking Therapeutics	20	116.65 million	110.47 million	Optionable

ABUS, VKTX, TLX, and IOVA Headlines

Recent News About These Companies

Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.

1 hour ago | fool.com

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

September 9 at 7:49 PM | finance.yahoo.com

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

September 9 at 6:50 PM | zacks.com

Viking Therapeutics Target of Unusually High Options Trading (NASDAQ:VKTX)

September 9 at 3:39 PM | marketbeat.com

Public Employees Retirement System of Ohio Purchases New Holdings in Viking Therapeutics, Inc. $VKTX

September 9 at 4:47 AM | marketbeat.com

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

September 8 at 2:10 PM | finance.yahoo.com

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

September 8 at 10:26 AM | zacks.com

Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.

September 5, 2026 | fool.com

Odyssean LLC Boosts Stake in Viking Therapeutics, Inc. $VKTX

September 5, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Takes $1.26 Million Position in Viking Therapeutics, Inc. $VKTX

September 5, 2026 | marketbeat.com

Concurrent Investment Advisors LLC Has $11.95 Million Stock Holdings in Viking Therapeutics, Inc. $VKTX

September 5, 2026 | marketbeat.com

Legal & General Group Plc Buys New Shares in Viking Therapeutics, Inc. $VKTX

September 5, 2026 | marketbeat.com

Is Viking Therapeutics (VKTX) Stock Fully Priced After A 411% Run?

September 4, 2026 | finance.yahoo.com

Jupiter Topco LLC Makes New Investment in Viking Therapeutics, Inc. $VKTX

September 4, 2026 | marketbeat.com

AXQ Capital LP Buys 56,796 Shares of Viking Therapeutics, Inc. $VKTX

September 4, 2026 | marketbeat.com

3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong

September 3, 2026 | fool.com

Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know

September 3, 2026 | finance.yahoo.com

Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know

September 3, 2026 | zacks.com

Viking Therapeutics to Participate at Upcoming Investor Conferences

September 2, 2026 | finance.yahoo.com

Viking Therapeutics to Participate at Upcoming Investor Conferences

September 2, 2026 | prnewswire.com

Quantitative Investment Management LLC Invests $1.61 Million in Viking Therapeutics, Inc. $VKTX

September 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS, VKTX, TLX, and IOVA Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$5.12 -0.06 (-1.06%)

As of 11:12 AM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Iovance Biotherapeutics NASDAQ:IOVA

$8.24 -0.19 (-2.19%)

As of 11:12 AM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Telix Pharmaceuticals NASDAQ:TLX

$12.09 -0.25 (-2.03%)

As of 11:11 AM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Viking Therapeutics NASDAQ:VKTX

$32.32 -0.39 (-1.18%)

As of 11:12 AM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABUS, VKTX, TLX, and IOVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABUS, VKTX, TLX, and IOVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABUS, VKTX, TLX, and IOVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS, VKTX, TLX, and IOVA Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Iovance Biotherapeutics NASDAQ:IOVA

Telix Pharmaceuticals NASDAQ:TLX

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABUS, VKTX, TLX, and IOVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABUS, VKTX, TLX, and IOVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABUS, VKTX, TLX, and IOVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS, VKTX, TLX, and IOVA Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Iovance Biotherapeutics NASDAQ:IOVA

Telix Pharmaceuticals NASDAQ:TLX

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools